Grace Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-15.8M | $-1.2M | $-2.3M | $-938.0K | $-3.4M | $636.0K | $-4.2M | $-3.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $2.0K | $2.0K | $3.0K | $0 | $2.0K | $2.0K | $2.0K | $2.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $105.0K | $182.0K | $108.0K | $206.0K | $302.0K | $130.0K | $160.0K | $202.0K |
| Net Cash from Operating Activities | $-3.2M | $-1.7M | $-2.2M | $-3.1M | $-1.8M | $-3.0M | $-4.1M | $-4.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | $0 | $0 | $0 | $0 | $15.0K | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $0 | $0 | $4.0M | $0 | $-327.0K | $14.0M | $0 | $0 |
| Net Change in Cash | $-3.2M | $-1.7M | $1.8M | $-3.1M | $-2.1M | $11.1M | $-4.1M | $-4.2M |
| Free Cash Flow | — | — | — | — | — | — | — | — |